Kidney Week

Abstract: SA-PO1270

Importance of the Onconephrology Outpatient Clinic in the Follow-Up and Clinical Outcomes of Patients with Cancer

Session Information

• Onconephrology: Epidemiological Trends, Risk Stratification, and Clinical Outcomes
  October 24, 2026 | Location: Exhibit Hall A, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Onconephrology

• 1600 Onconephrology

Authors

• Chaves, Marina Dornellas Camara de Almeida, Hospital das Clinicas da Universidade Federal de Pernambuco, Recife, PE, Brazil

Marina Dornellas Camara de Almeida Chaves, MD

• Paixão, Rafaella Barros da, Hospital das Clinicas da Universidade Federal de Pernambuco, Recife, PE, Brazil

Rafaella Barros da Paixão, MD

• Gueiros, Ana Paula, Hospital das Clinicas da Universidade Federal de Pernambuco, Recife, PE, Brazil

Ana Paula Gueiros, MD, PhD

• Batista, Maria Esilene Valença, Hospital das Clinicas da Universidade Federal de Pernambuco, Recife, PE, Brazil

Maria Esilene Valença Batista, MD

• Lopes, Lia Bastos, Hospital das Clinicas da Universidade Federal de Pernambuco, Recife, PE, Brazil

Lia Bastos Lopes, MEd

• Lopes, Matheus Rezende da Silva, Hospital das Clinicas da Universidade Federal de Pernambuco, Recife, PE, Brazil

Matheus Rezende da Silva Lopes

• Marques, Renan, Hospital das Clinicas da Universidade Federal de Pernambuco, Recife, PE, Brazil

Renan Marques

• Selva, Marina Wanderley, Hospital das Clinicas da Universidade Federal de Pernambuco, Recife, PE, Brazil

Marina Wanderley Selva

Background

Onconephrology is an important field of nephrology practice, enabling early kidney risk assessment, renoprotective strategies, and interdisciplinary follow-up of cancer patients. This study describes the experience of an onconephrology outpatient clinic, focusing on patient profile and clinical outcomes.

Methods

We retrospectively analyzed 148 medical records from patients followed between January 2023 and January 2026. Variables included demographics, referral reason, cancer type, comorbidities, renal replacement therapy (RRT), general interventions (diet, physical activity, nephrotoxic drugs withdrawal), antihypertensive adjustments, dyslipidemia treatment, and introduction of renoprotective medications. Serum creatinine (SCr – mg/dL), estimated glomerular filtration rate (eGFR, CKD-EPI), and annual eGFR slope were evaluated. Factors associated with eGFR decline and mortality were assessed.

Results

Median age was 66 years, 57.4% male, and median follow-up was 7,5 months. Solid tumors accounted for 79.7% of cases, and the main reason for referral was kidney dysfunction related to cancer or its treatment. Hypertension, dyslipidemia, diabetes, chronic kidney disease, and heart disease were present in 74%, 62%, 37%, 28%, and 12% of patients, respectively. Initial and final SCr values were 1.4 and 1.48 mg/dL, respectively. eGFR evolution was assessed in 120 patients, of whom 45% experienced decline, with a median slope of 7 mL/min/year. Patients with eGFR loss had higher final SCr levels (p<0.001). RRT was required in 12.8% of patients, and 3.4% remained on dialysis at the end of follow-up. Twenty-eight patients (18.9%) died. Deceased patients had higher rates of diabetes (p=0.04) and heart disease (p=0.001), underwent fewer general interventions (p=0.03), fewer renoprotective measures (p=0.04), and less dyslipidemia treatment (p=0.008). They also had higher final SCr (p=0.03) and greater eGFR decline (p=0.01). In multivariate analysis, heart disease (OR 3.06; p<0.001) and renal function decline (OR 3.33; p=0.002) were independently associated with mortality, whereas implementation of general measures was protective (OR 0.38; p=0.007).

Conclusion

Our results demonstrate the negative impact of comorbidities and kidney dysfunction on outcomes in cancer patients and highlight the importance of nephrology follow-up in mitigating renal injury and improving clinical outcomes.